scispace - formally typeset
Journal ArticleDOI

Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery.

Konstantinos Avgoustakis
- 30 Sep 2004 - 
- Vol. 1, Iss: 4, pp 321-333
TLDR
The ability of the PLA-Peg and PLGA-PEG nanoparticles to evade rapid phagocytocis has extended the range of sites within the body that the nanoparticles can reach, which has significant implications with regard to their application in controlled drug delivery and targeting.
Abstract
The preparation, properties and potential applications in drug delivery of biocompatible and biodegradable PLA-PEG and PLGA-PEG nanoparticles are discussed. PLA-PEG and PLGA-PEG nanoparticles have been produced by emulsification-solvent evaporation, solvent displacement and salting out methods. The nanoparticles can be stored as freeze-dried powders, but an adequate amount of a suitable lyoprotectant should be added prior lyophilisation to prevent nanoparticle aggregation and retain nanoparticle redispersibility. The nanoparticles have a core-shell structure with a PLA core and a PEG coating. Their basic colloidal properties and degradation depend on copolymer composition. The PLA-PEG and PLGA-PEG nanoparticles exhibit prolonged blood circulation following intravenous administration to animals. The composition of the nanoparticles determine their biodistribution properties, probably through its effects on the effectiveness of the PEG steric barrier and the size of the nanoparticles. The ability of the PLA-PEG and PLGA-PEG nanoparticles to evade rapid phagocytocis has extended the range of sites within the body that the nanoparticles can reach, which has significant implications with regard to their application in controlled drug delivery and targeting. The PLA-PEG and PLGA-PEG nanoparticles can be loaded with a variety of bioactive agents achieving satisfactory loading, especially in the case of hydrophobic drugs. The nanoparticles have been investigated for the treatment of infectious diseases and cancer, the intravenous and mucosal delivery of proteins, and oligonucleotide and gene delivery. The results have been encouraging and PLA-PEG and PLGA-PEG nanoparticle formulations, improving the therapeutic potential of both established and new drugs, may be expected to be available in the near future.

read more

Citations
More filters
Journal ArticleDOI

Folate-functionalized unimolecular micelles based on a degradable amphiphilic dendrimer-like star polymer for cancer cell-targeted drug delivery.

TL;DR: The in vitro cellular cytotoxicity indicated that the FA-DLSP micelles (without DOX) had good biocompatibility with KB cells, whereas DOX-loaded micells exhibited a similar degree of cytot toxicity against KB cells as that of free DOX.
Patent

High throughput fabrication of nanoparticles

TL;DR: In this article, a high throughput method of making nanoparticles that utilizes plates comprising wells (e.g., 96-well plates) was proposed for high throughput applications with high throughput.
Patent

Coated Controlled Release Polymer Particles as Efficient Oral Delivery Vehicles for Biopharmaceuticals

TL;DR: In this paper, a polymer core encapsulating the active agent and a muco-adhesive coating disposed about the core was used to facilitate transfer of the particle through the intestinal mucosa.
Journal ArticleDOI

Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.

TL;DR: PE38KDEL-loaded nanoparticles-anti-Fab' bioconjugates (PE-NPs-HER) had superior in vitro cytotoxicity against HER2-overexpressing breast cancer cell lines and may represent a potentially useful strategy for cancer therapy.
Patent

Stable formulations for lyophilizing therapeutic particles

TL;DR: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles as discussed by the authors.
Related Papers (5)